Stocks News

LAST PRICE
11.1500
TODAY'S CHANGE (%)
Trending Up1.3300 (13.5438%)

Bid / Lots
10.8000/ 1
Ask / Lots
11.3800/ 1
Open / Previous Close
11.1000 / 9.8200
Day Range
Low 10.6700
High 11.3100
52 Week Range
Low 6.9300
High 30.9580
Volume
2,245,194
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Today
- Immunome Insider Bought Shares Worth $962,181, According to a Recent SEC Filing, from 8 hours ago by MT Newswires
  8 hours ago by MT Newswires
  Companies Mentioned: IMNM
  09:05 AM EST, 11/25/2024 (MT Newswires) -- Clay B Siegall, Director, President and CEO, around November 21, 2024, executed a purchase for 100,000 shares in Immunome (IMNM) for $962,181. Following the Form 4 filing with the SEC, Siegall has control o...
Nov 22, 2024
- Immunome Files Prospectus for Stock Offering By Selling Shareholders, from 4:52PM ET on Friday Nov 22, 2024 by MT Newswires
  4:52PM ET on Friday Nov 22, 2024 by MT Newswires
  Companies Mentioned: IMNM
  04:52 PM EST, 11/22/2024 (MT Newswires) -- Immunome (IMNM) filed a prospectus late Friday for the sale of 1.8 million shares by selling shareholders from time to time. The shares covered in the prospectus were issued under the stock issuance agreeme...
Nov 14, 2024
- DJ Immunome Is Maintained at Overweight by Piper Sandler, from 7:35AM ET on Thursday Nov 14, 2024 by Dow Jones
  7:35AM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: IMNM
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNM/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 14, 2024 07:35 ET (12:35 GMT)
Nov 13, 2024
- Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: IMNM
  ---------- ---------- ---------- ---------- Net loss $ (47,100) $ (4,345) $ (212,714) $ (14,172) ========== ========== ========== ========== Net loss per share, basic and diluted $ (0.78) $ (0.36) $ (3.72) $ (1.16) ========== ========== ========== ========== Weighted-average shares outstanding, basic and diluted 60,205,327 12,202,335 57,239,668 12,194,277 ========== ========== ========== ========== Comprehensive loss Net loss $ (47,100) $ (4,345) $ (212,714) $ (14,172) Unrealized loss on marketable securities 68 -- 48 -- ---------- ---------- ---------- ---------- Comprehensive loss $ (47,032) $ (4,345) $ (212,666) $ (14,172) ========== ========== ========== ========== (1) Amounts include non-cash stock based compensation as follows (in thousands): Three Months Ended September 30, Nine Months Ended September 30, -------------------------- ------------------------------- 2024 2023 2024 2023 ------------ ------------ --------------- -------------- Research and development $ 1,820 $ 466 $ 3,244 $ 1,323 General and administrative 3,072 617 7,034 2,017 ---------- ---------- ---------- ---------- Total share-based compensation expense $ 4,892 $ 1,083 $ 10,278 $ 3,340 ========== ========== ========== ==========
- *DJ Immunome 3Q Loss/Shr 78c >IMNM, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
  Companies Mentioned: IMNM

Nov 20, 2024
- --Chardan Research Adjusts Price Target on Arbutus Biopharma to $5 From $4.50, Maintains Buy Rating, from 9:29AM ET on Wednesday Nov 20, 2024 by MT Newswires
  9:29AM ET on Wednesday Nov 20, 2024 by MT Newswires
  Companies Mentioned: ABUS
- DJ Arbutus Biopharma Is Maintained at Buy by Chardan Capital, from 6:09AM ET on Wednesday Nov 20, 2024 by Dow Jones
  6:09AM ET on Wednesday Nov 20, 2024 by Dow Jones
  Companies Mentioned: ABUS
Nov 19, 2024
- European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading, from 11:18AM ET on Tuesday Nov 19, 2024 by MT Newswires
  11:18AM ET on Tuesday Nov 19, 2024 by MT Newswires
  Companies Mentioned: NTZ, PUK, NGG, SQNS, GRFS, VRNA, AMRN, AKTX, MREO, BNTX, SLN, CRTO, DBVT, ADAP, SAN, EDAP
Nov 18, 2024
- European Equities Traded in the US as American Depositary Rise in Monday Trading, from 11:21AM ET on Monday Nov 18, 2024 by MT Newswires
  11:21AM ET on Monday Nov 18, 2024 by MT Newswires
  Companies Mentioned: NTZ, NVO, TEF, SQNS, GRFS, AMRN, OPRA, AKTX, MREO, SLN, EVAX, BP, TCBP, ASND, ADAP, BDRX
- DJ Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co., from 7:27AM ET on Monday Nov 18, 2024 by Dow Jones
  7:27AM ET on Monday Nov 18, 2024 by Dow Jones
  Companies Mentioned: ABUS
Nov 15, 2024
- Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results, from 12:27PM ET on Friday Nov 15, 2024 by MT Newswires
  12:27PM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: BRNS, ABUS
- European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week, from 11:09AM ET on Friday Nov 15, 2024 by MT Newswires
  11:09AM ET on Friday Nov 15, 2024 by MT Newswires
  Companies Mentioned: BBVA, LYG, PUK, ARGX, AKTX, MREO, BCYC, BNTX, EVAX, BTI, TCBP, DBVT, ASND, CLLS, SAN, BDRX
- Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon, from 11:02AM ET on Friday Nov 15, 2024 by Dow Jones
  11:02AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: ABUS
- Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B, from 11:01AM ET on Friday Nov 15, 2024 by Dow Jones
  11:01AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: BRNS, ABUS
- Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B, from 11:01AM ET on Friday Nov 15, 2024 by Dow Jones
  11:01AM ET on Friday Nov 15, 2024 by Dow Jones
  Companies Mentioned: ABUS

Immunome Inc
NASDAQ:IMNMUnited States

Search Criteria

Today

Immunome Insider Bought Shares Worth $962,181, According to a Recent SEC Filing, from 8 hours ago by MT Newswires

Nov 22, 2024

Immunome Files Prospectus for Stock Offering By Selling Shareholders, from 4:52PM ET on Friday Nov 22, 2024 by MT Newswires

Nov 14, 2024

DJ Immunome Is Maintained at Overweight by Piper Sandler, from 7:35AM ET on Thursday Nov 14, 2024 by Dow Jones

Nov 13, 2024

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

*DJ Immunome 3Q Loss/Shr 78c >IMNM, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones

Peers Headlines

Nov 20, 2024

--Chardan Research Adjusts Price Target on Arbutus Biopharma to $5 From $4.50, Maintains Buy Rating, from 9:29AM ET on Wednesday Nov 20, 2024 by MT Newswires

DJ Arbutus Biopharma Is Maintained at Buy by Chardan Capital, from 6:09AM ET on Wednesday Nov 20, 2024 by Dow Jones

Nov 19, 2024

European Equities Traded in the US as American Depositary Decline Slightly in Tuesday Trading, from 11:18AM ET on Tuesday Nov 19, 2024 by MT Newswires

Nov 18, 2024

European Equities Traded in the US as American Depositary Rise in Monday Trading, from 11:21AM ET on Monday Nov 18, 2024 by MT Newswires

DJ Arbutus Biopharma Price Target Maintained With a $5.00/Share by HC Wainwright & Co., from 7:27AM ET on Monday Nov 18, 2024 by Dow Jones

Nov 15, 2024

Arbutus Trial of Combination Therapy for Chronic Hepatitis B Shows 'Promising' Results, from 12:27PM ET on Friday Nov 15, 2024 by MT Newswires

European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week, from 11:09AM ET on Friday Nov 15, 2024 by MT Newswires

Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon, from 11:02AM ET on Friday Nov 15, 2024 by Dow Jones

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B, from 11:01AM ET on Friday Nov 15, 2024 by Dow Jones

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B, from 11:01AM ET on Friday Nov 15, 2024 by Dow Jones